BioCentury

7:00 AM GMT, Aug 29, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Emerging Company Profile

Novira: Capsid counterattack

Developing compounds against viral capsids is an attractive therapeutic strategy in theory, but has yet to work in practice because of the difficulty of inhibiting protein-protein interactions. Novira Therapeutics Inc. believes it has the right medicinal chemistry capabilities to develop small molecules that prevent capsid formation in HBV and HIV.

The capsid is a protein shell that forms around a virus to protect it during passage from one cell to another. "They do not have obvious binding sites, so there was

Read the full 805 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.